# Melanotan II: Evidence, Mechanism, Risks & Legal Status

> A clinical monograph on Melanotan II (MT-II) — the non-selective melanocortin agonist sold illegally for tanning. Thin 1990s human data, a high-risk safety profile, and an unapproved 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Melanotan II (MT-II) is one of the clearest cautionary tales in the peptide space: mechanistically elegant, clinically abandoned, and now a gray-market staple. What is genuinely studied is narrow — a three-person Phase I for UV-independent tanning and two ten-person crossovers for short-duration erection, both graded **B** — while the popular appetite claim is animal-only (**C**). It is FDA-unapproved, WADA-prohibited, carries a high-risk safety profile, and remains non-compoundable through 2026.[1](https://peptidevox.com/#r1)[17](https://peptidevox.com/#r17)

Melanotan II is a synthetic, cyclic alpha-melanocyte-stimulating-hormone (alpha-MSH) analog originally engineered at the University of Arizona as a pharmacologic tool and skin-cancer-prevention concept — to induce protective pigmentation without UV exposure.[1](https://peptidevox.com/#r1) Its popularity for sunless tanning and as a so-called "Barbie drug" is large; its proof in humans is tiny and dated. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Melanotan II is not an FDA-approved drug; it is sold illegally as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision; the safest path for cosmetic tanning is a topical DHA product, not an injectable melanocortin.*

## What is Melanotan II and how does it work?

MT-II is a synthetic cyclic heptapeptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, molecular formula C50H69N15O9, molar mass approximately 1024 — a lactam-bridged, conformationally constrained analog of native alpha-MSH.[4](https://peptidevox.com/#r4) The cyclization and the D-Phe substitution dramatically increase potency and metabolic stability versus the native linear hormone, the design rationale of Hruby and Hadley's University of Arizona program.[1](https://peptidevox.com/#r1)

The core mechanism is polypharmacology: MT-II is a non-selective agonist across the melanocortin GPCR family — MC1R, MC3R, MC4R and MC5R.[4](https://peptidevox.com/#r4) Activation of MC1R on melanocytes raises intracellular cAMP via adenylyl cyclase, drives PKA signaling, upregulates tyrosinase, and increases eumelanin synthesis — producing tanning independent of UV light.[5](https://peptidevox.com/#r5) Central MC4R in the hypothalamus is the principal mediator of MT-II's sexual-arousal and appetite-suppression effects, a centrally driven mechanism distinct from the vascular action of PDE5 inhibitors; MC3R and MC5R contribute to energy balance, inflammation and sebaceous/immune effects.[1](https://peptidevox.com/#r1) Critically, MT-II crosses the blood-brain barrier and engages central MC4R, which is why nausea and erections appear at tanning doses — the central effects cannot be dialed out, the key liability that halted its development.[1](https://peptidevox.com/#r1) Robust human pharmacokinetics for MT-II are not published; the foundational review reports no half-life data for the parent peptide, and the best proxy is its de-aminated metabolite bremelanotide (PT-141), which showed a peak serum concentration near 30 minutes and a serum half-life of roughly 120 minutes in Phase I.[1](https://peptidevox.com/#r1)

## What is the evidence by indication?

The human evidence base is thin, dated, and limited to a handful of subjects. Every indication below should be read in that light.

  Melanotan II evidence by indication

    IndicationBest evidenceGrade

    Skin tanning (UV-independent pigmentation)Pilot Phase I, single-blind, placebo-controlled, n=3 (2 of 3 tanned)B
    Erectile function / sexual arousalTwo double-blind placebo-controlled crossovers, n=10 each (psychogenic & organic ED)B
    Appetite suppression / weight lossRat central (intracerebroventricular) infusion only; no human studyC
    Skin-cancer preventionFounding hypothesis, never demonstrated in humans; undercut by melanoma case reportsD

The pivotal tanning evidence is the pilot Phase I trial (Dorr et al., *Life Sciences* 1996), a single-blind, alternating-day, placebo-controlled study in just three healthy men using subcutaneous dosing from 0.01 to 0.025-0.03 mg/kg/day; two of three subjects showed increased facial, upper-body and buttock pigmentation one week after dosing ended, without UV exposure.[2](https://peptidevox.com/#r2) The MC1R-to-cAMP/PKA-to-tyrosinase-to-eumelanin pathway is mechanistically well understood, but no human RCT has confirmed efficacy or safety.[5](https://peptidevox.com/#r5) For contrast, the MC1R-selective sibling afamelanotide (Scenesse, Melanotan I) is FDA-approved (2019) — but for erythropoietic protoporphyria, not cosmetic tanning.[4](https://peptidevox.com/#r4)

The erectile effect first emerged as an adverse finding in the 1996 tanning trial, then was formalized in two double-blind crossovers by Wessells and colleagues: in psychogenic ED, eight of ten men achieved erections with greater than 80 percent rigidity lasting a mean 38 minutes versus 3 minutes for placebo; in organic ED, subjective erections followed 63 percent of MT-II injections versus 5 percent of placebo, with increased subjective desire.[3](https://peptidevox.com/#r3) These are genuine controlled human data but tiny and short-duration, and the program pivoted to the cleaner metabolite bremelanotide, which reached FDA approval for female hypoactive sexual desire disorder (Vyleesi, 2019).[1](https://peptidevox.com/#r1) The widely marketed appetite and weight-loss claim, by contrast, rests on rat studies using direct brain infusion — which suppressed food intake by about 30 percent — not the subcutaneous route humans use, so it is preclinical-only.[14](https://peptidevox.com/#r14)[15](https://peptidevox.com/#r15) No adequately powered modern RCT exists for any indication; the WADA Prohibited List status can be confirmed at the [USADA Prohibited List](https://www.usada.org/substances/prohibited-list/).[19](https://peptidevox.com/#r19)

Proven vs hyped
Proven in humans: narrow, tiny tanning and erectile data (Grade B). Hyped: safe cosmetic tanning, weight loss, and cancer prevention — the weight claim is animal-only, and the cancer-prevention hypothesis is contradicted by real, if confounded, melanoma and dysplastic-nevus case reports.[6](https://peptidevox.com/#r6)[8](https://peptidevox.com/#r8)

## What doses appear in the literature?

Reported strictly as information, not a protocol — MT-II is unapproved and illegal for human use. All human and gray-market use is subcutaneous injection of reconstituted lyophilized peptide; it is not orally bioavailable.[2](https://peptidevox.com/#r2) The Phase I tanning trial started at 0.01 mg/kg/day SC and escalated by 0.005 mg/kg increments to 0.025-0.03 mg/kg/day, with 0.025 mg/kg/day recommended for future work; the 0.03 mg/kg dose produced Grade II somnolence and fatigue.[2](https://peptidevox.com/#r2) The erectile-function trials used single subcutaneous doses around 0.025 mg/kg (up to 0.157 mg/kg in dose-finding).[3](https://peptidevox.com/#r3) Gray-market users typically self-inject fixed milligram amounts — commonly a roughly 0.25-1 mg loading phase then intermittent maintenance — rather than weight-based dosing, a practice with no safety validation that is directly implicated in the toxicity case reports below.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12) Because the powder is reconstituted at home with no purity, sterility, or content guarantees, the formulation itself adds risk.[16](https://peptidevox.com/#r16)

## How safe is Melanotan II?

This compound has a high-risk safety profile, with reported adverse events spanning trivial to organ-threatening. Common dose-related effects from the controlled studies include nausea at essentially every dose level, vomiting, facial flushing, spontaneous erections, a characteristic yawning-stretching complex, and somnolence at higher doses.[2](https://peptidevox.com/#r2) The signature dermatologic concern is melanoma-spectrum: a 25-year-old developed sudden multiple new nevi and rapid change in existing ones weeks after a four-week course, with histopathology showing severe dysplasia, and melanoma case reports have been temporally associated with use — often confounded by concurrent sunbed exposure, including a teenage FAMMM-syndrome patient with an enlarging nevus after self-injection plus UV.[6](https://peptidevox.com/#r6)[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9) Causation is not proven and the data are case-report level, but the signal is biologically plausible because MT-II activates melanocytes regardless of whether a cell is normal or pre-malignant.[7](https://peptidevox.com/#r7) Melanonychia and oral mucosal pigmentation are also reported.[10](https://peptidevox.com/#r10)

Serious systemic events appear in the toxicology literature. Ischemic low-flow priapism has required cavernosal aspiration and intracavernosal phenylephrine, with some cases needing a surgical Winter's shunt and erectile function not recovered at follow-up.[13](https://peptidevox.com/#r13) A 39-year-old man who injected 6 mg subcutaneously developed tachycardia, hypertension, mydriasis, tremor, rhabdomyolysis and renal dysfunction requiring ICU care.[12](https://peptidevox.com/#r12) A previously normotensive man developed hypertension and a right-sided renal infarction affecting roughly half the kidney after 27 mg over six months, attributed to sympathetically driven vasoconstriction; posterior reversible encephalopathy syndrome and hypertensive crises are also reported.[11](https://peptidevox.com/#r11) The FDA has additionally flagged immunogenicity and impurity risks inherent to unregulated peptide products.[16](https://peptidevox.com/#r16) High-caution populations include those with personal or family history of melanoma or FAMMM, uncontrolled hypertension or cardiovascular disease, prior priapism or sickle-cell disease, and pregnancy or lactation where no data exist.[11](https://peptidevox.com/#r11)

## What is the FDA and WADA status in 2026?

Melanotan II has never been approved by the FDA for any medical, cosmetic, or therapeutic indication; it is treated as an unapproved new drug when sold or marketed for human use, and the FDA has issued warning letters and enforcement actions to distributors.[18](https://peptidevox.com/#r18) In September 2023 the FDA placed MT-II into 503A Category 2 — "significant safety risk" — effectively prohibiting its compounding.[16](https://peptidevox.com/#r16) On April 15, 2026 the FDA removed MT-II (with eleven other peptides including BPC-157 and TB-500) from Category 2, but removal from Category 2 is not authorization to compound; it merely lifts the explicit prohibition label.[17](https://peptidevox.com/#r17) To become compoundable, MT-II must clear a Pharmacy Compounding Advisory Committee review scheduled to convene before February 2027 and then notice-and-comment rulemaking, so it remains FDA-restricted and non-compoundable throughout 2026, with no legal human-use pathway.[17](https://peptidevox.com/#r17)

For athletes the picture is unambiguous: MT-II is captured as a peptide hormone under Section S2 of the WADA Prohibited List and should be treated as banned in and out of competition.[19](https://peptidevox.com/#r19) Do not conflate MT-II with its approved relatives — afamelanotide (Scenesse/Melanotan I), an MC1R-selective analog approved for EPP, or bremelanotide (Vyleesi/PT-141), MT-II's metabolite approved for female HSDD.[4](https://peptidevox.com/#r4)

**Bottom line.** MT-II's non-selectivity is an un-fixable design flaw for human use — the very reason industry shelved it and advanced the cleaner metabolite bremelanotide. What is genuinely studied is minimal (Grade B tanning and erection), the popular appetite claim is animal-only (C), and what is hyped is contradicted by a real if confounded dermatologic safety signal plus organ-level toxicity. It remains unapproved, WADA-prohibited, and FDA-restricted in 2026, with key uncertainties — absolute melanoma risk, long-term cardiovascular consequences, and product purity — all unknown precisely because no regulated trial program exists. Regulatory facts here are current as of June 2026 and should be re-verified after the PCAC review.

---
Source: https://peptidevox.com/peptide-encyclopedia/melanotan-2
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt